Author: Bertolini, Anna; van de Peppel, Ivo P.; Bodewes, Frank A.J.A.; Moshage, Han; Fantin, Alberto; Farinati, Fabio; Fiorotto, Romina; Jonker, Johan W.; Strazzabosco, Mario; Verkade, Henkjan J.; Peserico, Giulia
Title: Abnormal liver function tests in COVIDâ€19 patients: relevance and potential pathogenesis Cord-id: e9tx5tqm Document date: 2020_7_23
ID: e9tx5tqm
Snippet: Abnormal liver function tests (LFTs) are reported frequently in hospitalized coronavirus disease 2019 (COVIDâ€19) patients. A review of the literature shows that 46% of admitted COVIDâ€19 patients had elevated plasma aspartate aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT) levels on admission. Elevations of both AST and ALT are mostly below 5 times the upper reference limit and are associated with severe disease and increased inflammatory markers. AST and ALT elevat
Document: Abnormal liver function tests (LFTs) are reported frequently in hospitalized coronavirus disease 2019 (COVIDâ€19) patients. A review of the literature shows that 46% of admitted COVIDâ€19 patients had elevated plasma aspartate aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT) levels on admission. Elevations of both AST and ALT are mostly below 5 times the upper reference limit and are associated with severe disease and increased inflammatory markers. AST and ALT elevations are more frequent in US patients compared to Chinese patients. Mild elevations in gammaâ€glutamyltransferase (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although less frequently. Significant impairment of liver function or overt liver failure as the cause of death in COVIDâ€19 rarely occur. There is no direct evidence of severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) hepatic infection, although a subset of hepatocytes and cholangiocytes express the host receptor utilized for cellular entry by SARSâ€CoVâ€2. The presence of preâ€existing liver disease in patients with elevated LFTs on admission has not been comprehensively assessed in most studies but is unlikely to account for all abnormalities in LFTs. Although abnormal LFTs are already frequently present upon admission before the start of treatment, drugâ€induced liver injury should be taken into consideration, especially after the use of acetaminophen, lopinavir/ritonavir and remdesivir, which are potentially hepatotoxic. In conclusion, these initial observations suggest that the prevalence of abnormal LFTs is high in COVIDâ€19 patients, but that the clinical relevance is limited and that treatment is not required. The mechanisms underlying abnormal LFTs in COVIDâ€19 are likely multifactorial and related to a hyperâ€inflammatory status and thrombotic microangiopathy that are observed in severe COVIDâ€19 disease.
Search related documents:
Co phrase search for related documents- liver disease and luminal thrombosis: 1, 2
- liver disease and macrophage activation: 1, 2, 3, 4
- liver disease and mafld fatty liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- liver disease and mafld obesity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- liver disease and mafld prevalence: 1, 2, 3, 4
- liver function and luminal thrombosis: 1
- liver function and macrophage activation: 1, 2, 3
- liver function and mafld fatty liver disease: 1
- liver function and mafld prevalence: 1
- liver transplant and lung compliance: 1
- liver transplant and macrophage activation: 1
- low grade inflammation and macrophage activation: 1
- low grade inflammation and mafld fatty liver disease: 1, 2, 3
- low grade inflammation and mafld obesity: 1
Co phrase search for related documents, hyperlinks ordered by date